# Section 1: Identification

**Material**
Potassium Chloride Extended-Release Capsules USP 600 mg (8mEq K) and 750 mg (10 mEq K)

**Manufacturer**
Lupin Limited  
Pithampur (M.P.) - 454 775  
INDIA  

**Distributor**
Lupin Pharmaceuticals, Inc.  
111 South Calvert Street,  
Harborplace Tower, 21st Floor,  
Baltimore, Maryland 21202  
United States  
Tel. 001-410-576-2000  
Fax. 001-410-576-2221

---

# Section 2: Hazard(s) Identification

**Section 2, Hazard(s) identification**

**Fire and Explosion**
Expected to be non-combustible.

**Health**
Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Hyperkalemia may complicate any of the following conditions: chronic renal failure, systemic acidosis such as diabetic acidosis, acute dehydration, extensive tissue breakdown as in severe burns, adrenal insufficiency, or the administration of a potassium-sparing diuretic (e.g., spironolactone, triamterene, amiloride). Controlled-release formulations of potassium chloride have produced esophageal ulceration in certain cardiac patients with esophageal compression due to an enlarged left atrium. Potassium supplementation, when indicated in such patients, should be given as a liquid preparation. All solid oral dosage forms of potassium chloride are contraindicated in any patient in whom there is structural, pathological (e.g., diabetic gastroparesis) or pharmacologic (use of anticholinergic agents or other agents with anticholinergic properties at sufficient doses to exert anticholinergic effects) cause for arrest or delay in capsule passage through the gastrointestinal tract.

**Environment**
No information is available about the potential of this product to produce adverse environmental effects.
Section 3: Composition/Information on Ingredients

Section 3, Composition/information on ingredients

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>CAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Potassium Chloride USP</td>
<td>7447-40-7</td>
</tr>
</tbody>
</table>

Section 4: First-Aid Measures

Section 4, First-aid measures

**Ingestion**

If conscious, give water to drink and induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. Obtain medical attention.

**Inhalation**

Move individual to fresh air. Obtain medical attention if breathing difficulty occurs. If not breathing, provide artificial respiration assistance.

**Skin Contact**

Remove contaminated clothing and flush exposed area with large amounts of water. Wash all exposed areas of skin with plenty of soap and water. Obtain medical attention if skin reaction occurs.

**Eye Contact**

Flush eyes with plenty of water. Get medical attention.

NOTES TO HEALTH PROFESSIONALS

**Medical Treatment**

Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

**OVERDOSAGE**

The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal hyperkalemia can result. It is important to recognize that hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of ST segment, and prolongation of the QT interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).

Treatment measures for hyperkalemia include the following: (1) elimination of foods and medications containing potassium and of any agents with potassium-sparing properties; (2) intravenous administration of 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL; (3) correction of acidosis, if present, with intravenous sodium...
bicarbonate; (4) use of exchange resins, hemodialysis, or peritoneal dialysis. In treating hyperkalemia, it should be recalled that in patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity. The extended release feature means that absorption and toxic effects may be delayed for hours. Consider standard measures to remove any unabsorbed drug.

### Section 5: Fire-Fighting Measures

**Section 5, Fire-fighting measures**

<table>
<thead>
<tr>
<th>Fire and Explosion Hazards</th>
<th>Assume that this product is capable of sustaining combustion.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extinguishing Media</td>
<td>Water spray, carbon dioxide, dry chemical powder or appropriate foam.</td>
</tr>
<tr>
<td>Special Firefighting Procedures</td>
<td>For single units (packages): No special requirements needed.</td>
</tr>
<tr>
<td></td>
<td>For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.</td>
</tr>
<tr>
<td>Hazardous Combustion Products</td>
<td>Hazardous combustion or decomposition products are expected when the product is exposed to fire.</td>
</tr>
</tbody>
</table>

### Section 6: Accidental Release Measures

**Section 6, Accidental release measures**

<table>
<thead>
<tr>
<th>Personal Precautions</th>
<th>Wear protective clothing and equipment consistent with the degree of hazard.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Environmental Precautions</td>
<td>For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.</td>
</tr>
<tr>
<td>Clean-up Methods</td>
<td>Collect and place it in a suitable, properly labeled container for recovery or disposal.</td>
</tr>
</tbody>
</table>

### Section 7: Handling and Storage

**Section 7, Handling and storage**

<table>
<thead>
<tr>
<th>Handling</th>
<th>No special control measures required for the normal handling of this product.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Normal room ventilation is expected to be adequate for routine handling of this product.</td>
</tr>
</tbody>
</table>
**Storage**

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight container.

---

**Section 8: Exposure Controls/ Personal Protection**

Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

---

**Section 9: Physical and Chemical Properties**

Section 9, Physical and chemical properties

**Physical Form**

Potassium Chloride Extended-Release Capsules USP, 600 mg (8 mEq K) are size ‘00’ opaque white color hard gelatin capsules imprinted with ‘LU’ on cap and ‘R51’ on body in black ink containing white to off white coated pellets (equivalent to 8 mEq K) in bottles of 100 (NDC 68180-798-01) and bottles of 500 (NDC 68180-798-02).

Potassium Chloride Extended-Release Capsules USP, 750 mg (10 mEq K) are size ‘00 EL’ opaque blue color hard gelatin capsules imprinted with ‘LU’ on cap and ‘R52’ on body in white ink containing white to off white coated pellets (equivalent to 10 mEq K) in bottles of 100 (NDC 68180-799-01), bottles of 500 (68180-799-02) and bottles of 1000 (68180-799-03).

---

**Section 10: Stability and Reactivity**

Section 10, Stability and reactivity

Stable under recommended storage conditions.

---

**Section 11: Toxicological Information**

Section 11, Toxicological information

**Carcinogenesis, mutagenesis, impairment of fertility**

Carcinogenicity, mutagenicity and fertility studies in animals have not been performed. Potassium is a normal dietary constituent.

---

**Section 12: Ecological Information**

Section 12: Ecological Information

No relevant studies identified.
Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

Section 14: Transport Information

Section 14: Transport Information

IATA/ICAO - Not Regulated
IATA Proper shipping Name : N/A
IATA UN/ID No : N/A
IATA Hazard Class : N/A
IATA Packaging Group : N/A
IATA Label : N/A

IMDG - Not Regulated
IMDG Proper shipping Name : N/A
IMDG UN/ID No : N/A
IMDG Hazard Class : N/A
IMDG Flash Point : N/A
IMDG Label : N/A

DOT - Not Regulated
DOT Proper shipping Name : N/A
DOT UN/ID No : N/A
DOT Hazard Class : N/A
DOT Flash Point : N/A
DOT Packing Group : N/A
DOT Label : N/A

Section 15: Regulatory Information

Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

Section 16: Other Information

Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Lupin shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this MSDS.